A pattern discovery framework for adverse event evaluation and inference in spontaneous reporting systems
暂无分享,去创建一个
[1] N. Laird,et al. Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention , 1995 .
[2] Marianthi Markatou,et al. Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection , 2011, J. Am. Medical Informatics Assoc..
[3] S D Small,et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. , 1998, JAMA.
[4] Maria-Florina Balcan,et al. A theory of learning with similarity functions , 2008, Machine Learning.
[5] D. Classen,et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.
[6] D Madigan,et al. Logistic Regression in Signal Detection: Another Piece Added to the Puzzle , 2013, Clinical pharmacology and therapeutics.
[7] Albert,et al. Emergence of scaling in random networks , 1999, Science.
[8] G. Peter,et al. Intussusception, rotavirus, and oral vaccines: summary of a workshop. , 2002, Pediatrics.
[9] Alan J. Forster,et al. A systematic review to evaluate the accuracy of electronic adverse drug event detection , 2012, J. Am. Medical Informatics Assoc..
[10] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[11] A. Tversky. Features of Similarity , 1977 .
[12] R Ball,et al. Simulating adverse event spontaneous reporting systems as preferential attachment networks , 2014, Applied Clinical Informatics.
[13] Guy E. Thwaites,et al. The Diagnosis and Management of Tuberculous Meningitis , 2002, Practical Neurology.
[14] Taxiarchis Botsis,et al. Application of Information Retrieval Approaches to Case Classification in the Vaccine Adverse Event Reporting System , 2013, Drug Safety.
[15] David R. Cox,et al. On the consequences of overstratification , 2008 .
[16] P. McCullagh. Sampling bias and logistic models , 2008 .
[17] D. Bates,et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.
[18] Maria-Florina Balcan,et al. Improved Guarantees for Learning via Similarity Functions , 2008, COLT.
[19] Robert Ball,et al. Network Analysis of Possible Anaphylaxis Cases Reported to the US Vaccine Adverse Event Reporting System after H1N1 Influenza Vaccine , 2011, MIE.
[20] Santosh S. Vempala,et al. A discriminative framework for clustering via similarity functions , 2008, STOC.
[21] Peter J. Bickel,et al. The Earth Mover's distance is the Mallows distance: some insights from statistics , 2001, Proceedings Eighth IEEE International Conference on Computer Vision. ICCV 2001.
[22] Jun Li,et al. Thresholding Events of Extreme in Simultaneous Monitoring of Multiple Risks , 2009 .
[23] D. Madigan,et al. The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.
[24] Jan Bonhoeffer,et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. , 2007, Vaccine.
[25] Stefan Arnborg,et al. A bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets , 2005, Int. J. Neural Syst..
[26] C Chuang-Stein,et al. Organization and analysis of safety data using a multivariate approach. , 1992, Statistics in medicine.
[27] D. Clayton. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence , 1978 .
[28] D. W. Goodall. A New Similarity Index Based on Probability , 1966 .
[29] J Lellouch,et al. Power and weakness of spontaneous reporting: a probabilistic approach. , 1992, Journal of clinical epidemiology.
[30] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[31] F Thiessard,et al. False Discovery Rate Estimation for Frequentist Pharmacovigilance Signal Detection Methods , 2010, Biometrics.
[32] Pamela W Ewan,et al. ABC of allergies: Anaphylaxis , 1998 .
[33] C. Manski. Anatomy of the Selection Problem , 1989 .
[34] Jesse A Berlin,et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team , 2009, Clinical trials.
[35] N. Laird,et al. Incidence of adverse drug events and potential adverse drug events , 1995 .
[36] Fei Wang,et al. Case-based reasoning in comparative effectiveness research , 2012, IBM J. Res. Dev..
[37] P. Scheinmann,et al. Vaccine allergy and pseudo-allergy. , 2003, European journal of dermatology : EJD.
[38] Claudia Czado,et al. Pair Copula Constructions for Multivariate Discrete Data , 2012 .
[39] Robert Ball,et al. Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data. , 2005, Statistics in medicine.
[40] Michael Schwenk,et al. Anaphylaxis , 1919, The Indian medical gazette.
[41] R Ball,et al. Can Network Analysis Improve Pattern Recognition Among Adverse Events Following Immunization Reported to VAERS? , 2011, Clinical pharmacology and therapeutics.
[42] A. Egberts,et al. Adverse drug events in hospitalized patients A comparison of doctors, nurses and patients as sources of reports , 1999, European Journal of Clinical Pharmacology.
[43] R. Tiwari,et al. A Likelihood Ratio Test Based Method for Signal Detection With Application to FDA’s Drug Safety Data , 2011 .
[44] T. M. F. Smith,et al. On the validity of interferences from non-random samples , 1983 .
[45] Andrew Bate,et al. Terminological Challenges in Safety Surveillance , 2012, Drug Safety.
[46] George Hripcsak,et al. A statistical methodology for analyzing co-occurrence data from a large sample , 2007, J. Biomed. Informatics.
[47] D. Classen,et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.
[48] N. Shah,et al. Performance of Pharmacovigilance Signal‐Detection Algorithms for the FDA Adverse Event Reporting System , 2013, Clinical pharmacology and therapeutics.
[49] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[50] Duncan C. L. Fitzwilliams,et al. Intussusception , 1903, The Hospital.
[51] S. Evans,et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.
[52] Johan Hopstadius,et al. Impact of Stratification on Adverse Drug Reaction Surveillance , 2008, Drug safety.
[53] D. Bates,et al. The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .
[54] Marián Boguñá,et al. Popularity versus similarity in growing networks , 2011, Nature.
[55] D. Madigan,et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership , 2012, Statistics in medicine.
[56] J J Rybacki,et al. Adverse drug events in hospitalized patients. , 1997, JAMA.
[57] Pravin K. Trivedi,et al. Using Trivariate Copulas to Model Sample Selection and Treatment Effects , 2006 .
[58] B. Schwartz,et al. Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.
[59] Christy Chuang-Stein,et al. Safety Analysis in Controlled Clinical Trials , 1998 .
[60] Patrick B. Ryan,et al. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases , 2012, J. Biomed. Informatics.
[61] Manfred Hauben,et al. Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions , 2009, Drug safety.
[62] Jelena Savović,et al. Methods for Causality Assessment of Adverse Drug Reactions , 2008, Drug safety.
[63] J. Heckman. Sample selection bias as a specification error , 1979 .
[64] Marie Lindquist,et al. The Need for Definitions in Pharmacovigilance , 2007, Drug safety.
[65] 朱丽琳,et al. Anaphylaxis , 2006 .
[66] J. Gower. A General Coefficient of Similarity and Some of Its Properties , 1971 .
[67] J. Copas,et al. Inference for Non‐random Samples , 1997 .
[68] F Thiessard,et al. Pharmacovigilance Data Mining With Methods Based on False Discovery Rates: A Comparative Simulation Study , 2010, Clinical pharmacology and therapeutics.
[69] D. Oakes,et al. Bivariate survival models induced by frailties , 1989 .
[70] David J. Hand,et al. Pattern Discovery and Detection: A Unified Statistical Methodology , 2004 .
[71] R. Holman,et al. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. , 1998, The Pediatric infectious disease journal.
[72] W. Amery. Why there is a need for pharmacovigilance , 1999, Pharmacoepidemiology and drug safety.
[73] P Ryan,et al. Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis , 2012, Clinical pharmacology and therapeutics.
[74] D. Madigan,et al. Evaluating the impact of database heterogeneity on observational study results. , 2013, American journal of epidemiology.
[75] S D Small,et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. , 1995, The Joint Commission journal on quality improvement.
[76] George Hripcsak,et al. Use abstracted patient-specific features to assist an information-theoretic measurement to assess similarity between medical cases , 2008, J. Biomed. Informatics.
[77] Thomas P. Gross,et al. The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety , 2012, Pharmacoepidemiology and drug safety.
[78] Peter C Austin,et al. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies , 2010, Statistics in medicine.
[79] Arvind Madaan,et al. Vaccine allergy: diagnosis and management. , 2003, Immunology and allergy clinics of North America.